Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Osnat Bohana-Kashtan

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Stem Cells (Dayton, Ohio)|November 13, 2004
Fas ligand as a tool for immunosuppression and generation of immune toleranceOsnat Bohana-Kashtan, Curt I Civin
European Journal of Immunology|May 20, 2005
Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysisOsnat Bohana-Kashtan, Lorenzo A Pinna, Zvi Fishelson
Transplantation|August 24, 2006
Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host diseaseRobert W Georgantas, Osnat Bohana-Kashtan, Curt I Civin
Molecular Immunology|June 29, 2004
Cell signals transduced by complementOsnat Bohana-Kashtan, Lea Ziporen, Natalie Donin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2009
Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligandOsnat Bohana-Kashtan, Sebastien Morisot, Richard Hildreth, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2012
1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinaseAvihai Yacovan, Rachel Ozeri, Tzofit Kehat, et al.
Translational Vision Science & Technology|June 20, 2017
Long-Term Efficacy of GMP Grade Xeno-Free hESC-Derived RPE Cells Following TransplantationTrevor J McGill, Osnat Bohana-Kashtan, Jonathan W Stoddard, et al.
Nature Medicine|May 27, 2020
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trialBruno Bockorny, Valerya Semenisty, Teresa Macarulla, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Stem Cells (Dayton, Ohio)|November 13, 2004
Fas ligand as a tool for immunosuppression and generation of immune toleranceOsnat Bohana-Kashtan, Curt I Civin
European Journal of Immunology|May 20, 2005
Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysisOsnat Bohana-Kashtan, Lorenzo A Pinna, Zvi Fishelson
Transplantation|August 24, 2006
Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host diseaseRobert W Georgantas, Osnat Bohana-Kashtan, Curt I Civin
Molecular Immunology|June 29, 2004
Cell signals transduced by complementOsnat Bohana-Kashtan, Lea Ziporen, Natalie Donin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2009
Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligandOsnat Bohana-Kashtan, Sebastien Morisot, Richard Hildreth, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2012
1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinaseAvihai Yacovan, Rachel Ozeri, Tzofit Kehat, et al.
Translational Vision Science & Technology|June 20, 2017
Long-Term Efficacy of GMP Grade Xeno-Free hESC-Derived RPE Cells Following TransplantationTrevor J McGill, Osnat Bohana-Kashtan, Jonathan W Stoddard, et al.
Nature Medicine|May 27, 2020
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trialBruno Bockorny, Valerya Semenisty, Teresa Macarulla, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
Pageof 1